RallyBio tries again for reverse merger, this time with Avenzo
RallyBio, which abandoned a reverse merger with Candid Therapeutics after the plan dissolved, announced a new reverse merger with Avenzo Therapeutics, according to the deal announced Monday. The combined company will trade on Nasdaq as AVZO, raise $215 million, and is expected to close by year-end. RallyBio has faced layoffs and disappointing results since going public in 2021.
How this was made
The 30-second read
Why it matters
The announcement resets the corporate-action narrative for RLYB and creates a new trading vehicle (AVZO) tied to Avenzo’s early-stage oncology pipeline and a fresh $215M financing, with deal close targeted by year-end.
Market read
A fresh reverse merger plus new financing and pipeline/data highlights can drive speculative positioning and volatility ahead of deal-close milestones.
What to watch
Key deal terms (exchange ratio, cash at close, dilution) and the quality/interpretation of the ASCO Phase 1 data are not detailed here, which can dominate near-term price action.
Background
RallyBio (public since 2021) previously attempted a reverse merger with Candid Therapeutics, which later dissolved; Candid is instead being acquired by UCB.
Ticker impact
RallyBio’s reverse-merger attempt with Candid dissolved, and it is now pursuing a new merger with Avenzo Therapeutics.
High volatility likely around deal-close expectations and any financing/terms updates.
The article is a breaking deal update for the listed target (RLYB), but it doesn’t provide valuation terms beyond financing size and expected close timing.
Market effects
Reinforces ongoing appetite for oncology small-molecule/ADC platforms via reverse mergers and Chinese-biotech-derived assets.
Primarily US-listed biotech capital markets; could influence sentiment toward Nasdaq-listed clinical-stage reverse-merger candidates.
Highlights cross-border biotech asset flows (Chinese-origin programs) into US public markets.
Counterpoint
The prior RallyBio merger failed; this second attempt may signal structural financing/clinical-risk issues rather than a durable turnaround.
Key entities
- public companyRallyBio
Struggling drugmaker attempting a second reverse merger after the Candid deal dissolved.
- target companyAvenzo Therapeutics
Cancer drug developer whose programs will be brought into a Nasdaq-listed combined entity.
- target companyCandid Therapeutics
Previous merger target that instead agreed to be acquired by UCB.
- acquirerUCB
Agreed to acquire Candid in a $2.2B transaction.
- asset sourcesVelaVigo / DualityBio / Allorion Therapeutics
Companies whose experimental cancer drugs were acquired by Avenzo.
